Author Archives: Admin

Lassa fever is a viral haemorrhagic disease endemic to West Africa, caused by the Lassa virus and primarily transmitted through exposure to food or surfaces contaminated by infected rodents. Human-to-human transmission can also occur, particularly in healthcare settings without adequate infection control. Symptoms range from mild fever and weakness to severe complications such as bleeding, organ failure, and, in some cases, death.

Nigeria continues to experience seasonal outbreaks, and recent data from the Nigeria Centre for Disease Control and Prevention shows that 2026 is following a concerning trajectory.

As of Epidemiological Week 8 (February 2026):

• 404 confirmed cases have been recorded





• 99 deaths, with a case fatality rate (CFR) of 24.5%





• Cases have spread across 18 states and 67 Local Government Areas

While weekly confirmed cases have slightly declined (77 new cases in Week 8 compared to 82 in Week 7), the rising fatality rate higher than 18.8% in 2025 signals ongoing gaps in early detection and treatment access.

More recent updates suggest the trend persists. By March 2026, Nigeria had recorded over 580 confirmed cases and more than 140 deaths, maintaining a high fatality rate above 24%.

Geographic and Demographic Trends

The outbreak remains highly concentrated:

• Bauchi (30%), Ondo (21%), and Taraba (19%) account for the majority of cases





• Together with Edo and Benue, these states contribute 84% of all confirmed infections

The most affected group is young adults aged 21–30, although cases span from infants to older adults. Men are slightly more affected than women (ratio 1:0.8).

Healthcare workers also remain at risk, with new infections recorded among frontline responders highlighting persistent vulnerabilities in infection prevention systems.

Treatment Gaps and a New Breakthrough

Currently, treatment options for Lassa fever are limited. The antiviral drug ribavirin is widely used but is most effective only when administered early, which is often not the case due to delayed diagnosis.

However, new research published in Nature introduces a promising development. Scientists have identified an oral antiviral drug, 4′-fluorouridine (4′-FIU), that demonstrated strong efficacy in treating Lassa fever in nonhuman primates.

Key findings from the study include:

• Effectiveness even when treatment begins several days after infection





• Significant reduction in viral load





• Improved survival outcomes

This is particularly important because Lassa fever is often diagnosed late, when existing treatments are less effective. An oral drug also offers practical advantages for deployment in rural and resource-limited settings.

What This Means for Public Health in Africa

The combination of rising fatality rates and continued geographic spread underscores the urgency of improving surveillance, diagnostics, and treatment access.

At the same time, advances like 4′-FIU highlight the role of genomics, antiviral research, and global collaboration in addressing endemic diseases.

While the drug is still in the experimental stage and requires human clinical trials, it represents a potential shift in how Lassa fever is treated especially in regions where early intervention is difficult.

Lassa fever remains a persistent and evolving public health challenge in Nigeria. But with improved data tracking and emerging therapeutic innovations, there is a clear pathway toward better outcomes and reduced mortality if investments in research, healthcare systems, and community awareness continue.

Read more on the Lassa fever trend in Nigeria .

Trusted DNA Testing Services in Nigeria

MyAfroDNA provides reliable and confidential DNA testing services in Nigeria for individuals, families, legal professionals, and institutions. Whether you need a paternity DNA test, immigration DNA test, or other relationship testing services, our process is handled with professionalism and strict laboratory standards.

We serve clients across Lagos, Abuja, Port Harcourt, Rivers State, and other cities nationwide.

If you are searching for where to get a DNA test done in Nigeria, MyAfroDNA offers trusted and accurate solutions.

Paternity DNA Testing in Nigeria

Our paternity DNA test determines biological fatherhood with over 99.99% accuracy. This service is available for:

• Peace-of-mind testing





• Legal and court-admissible testing





• Family confirmation purposes

Each test follows secure sample collection procedures and professional laboratory processing to ensure reliable and confidential results.

MyAfroDNA provides paternity DNA testing services across Nigeria with discretion and scientific precision.

Immigration & Legal DNA Testing

MyAfroDNA provides immigration DNA testing services for embassy and visa requirements. Our documentation process follows internationally recognized standards to ensure accurate and legally acceptable results.

We assist families and individuals throughout Nigeria who require DNA testing for official purposes.

Sibling & Relationship DNA Testing

In addition to paternity testing, we provide:

• Sibling DNA testing





• Maternity testing





• Grandparent DNA testing





• Other biological relationship verification services

All tests are conducted using scientifically validated procedures to ensure high levels of accuracy.

Why Choose MyAfroDNA for DNA Testing in Nigeria?

• Accurate and reliable DNA test results





• Strict confidentiality and data protection





• Nationwide service coverage





• Professional laboratory standards





• Efficient turnaround times





• Experienced scientific team

MyAfroDNA combines biotechnology expertise with accessible DNA testing services tailored to individuals and institutions across Nigeria.

DNA Testing Available Nationwide

We provide DNA testing services in:

• Port Harcourt





• Lagos





• Abuja





• Rivers State





• Other locations across Nigeria

If you are searching for “DNA test near me” in Nigeria, our team is available to guide you through the process professionally and confidentially.

Frequently Asked Questions

How much does a DNA test cost in Nigeria?
Our DNA Paternity test is the cheapest in Nigeria and costs 150,000 naira only. Additional charges may apply for shipment of samples or the type of test required. Contact MyAfroDNA directly for current pricing and consultation.

How long does a paternity DNA test take in Nigeria?
Our turnaround time is seven days and can be expedited in cases of emergencies. Our team provides clear timelines during bookings.

Is DNA testing confidential?
Yes. All DNA testing services at MyAfroDNA are handled with strict confidentiality and data protection standards.

Book a DNA Test in Nigeria

To schedule your DNA test appointment, contact MyAfroDNA today.

Call us on 07010644048
Or send us a WhatsApp message on 07010644048 to book an appointment

Our team will guide you through the process professionally and d

Recently, MyAfroDNA announced the acquisition of the CycloneSEQ sequencer nanopore genome sequencing platform, becoming the first facility in West Africa to deploy this advanced technology. This milestone represents a significant advancement for genome sequencing in Nigeria, biotechnology in West Africa, and African-led genomics research.

But what exactly is the CycloneSEQ platform? How does nanopore sequencing work? And why does this matter for researchers, institutions, and biotech organizations across Africa and globally?

In this article, we explain:

• What the CycloneSEQ platform does





• The science behind its enhanced protein engineering and flow cell design





• Its advantages over traditional sequencing systems





• Why long-read sequencing is critical for modern genomics





• How institutions can collaborate with MyAfroDNA

What Is the CycloneSEQ Nanopore Sequencing Platform?

The CycloneSEQ platform, including the CycloneSEQ-WT02 and CycloneSEQ-WY01 models, is an advanced nanopore-based genome sequencing system developed by MGI Tech Co., Ltd. Unlike conventional short-read sequencing platforms that fragment DNA into small pieces for computational assembly, nanopore sequencing reads long DNA molecules directly as they pass through nanoscale protein pores.

As DNA passes through each nanopore, changes in electrical current are detected at picoampere resolution. These signals are then decoded in real time using advanced basecalling algorithms.

This enables:

• Long-read genome sequencing





• Real-time data generation





• Structural variant detection





• Whole genome assembly





• Metagenomics and pathogen surveillance





• Agricultural and biodiversity genomics

For biotechnology in Nigeria and West Africa, this introduces a new level of sequencing capability previously unavailable locally.

Advanced Technology Behind CycloneSEQ

The CycloneSEQ platform integrates several major innovations that elevate its performance in genomic applications.

Enhanced Protein Engineering

CycloneSEQ utilizes:

• A high thermal stability motor protein





• A structurally rigid nanopore protein

This refined structure improves:

• DNA unwinding efficiency





• Nucleic acid capture





• Reduced sequencing noise





• Signal stability

These enhancements increase threading precision as DNA passes through the pore, significantly improving sequencing reliability.

High-Density Flow Cell Architecture

Each flow cell supports up to 4,096 nanopore protein sensors arranged in a high-density array.

The integration of:

• BioMEMS microfluidic control systems





• ASIC-based electronic signal processing

Allows ultra-sensitive detection of current changes at picoampere levels.

This enables:

• Stable, ultra-long sequencing runs





• High-throughput genomic analysis





• Multi-flow cell scalability





• Continuous real-time sequencing

Optimized Basecalling Algorithm (97% Accuracy)

CycloneSEQ employs a proprietary basecalling algorithm trained using large-scale distributed computing.

With reported accuracy rates of approximately 97%, the system delivers:

• Real-time DNA sequence decoding





• Reliable variant detection





• Reduced computational post-processing





• Improved structural variant resolution

This level of optimization is critical for clinical research, agricultural genomics, and biodiversity projects.

Innovative Nanopore Local Chemistry

A novel sequencing chemistry modulates magnesium ion electrophoretic migration to regulate motor protein activity.

This chemistry improves:

• DNA translocation control





• Sequencing efficiency





• Signal clarity





• Run stability

Together, these innovations position CycloneSEQ as a highly competitive long-read sequencing platform.

CycloneSEQ vs Traditional Sequencing Platforms

Understanding the distinction between long-read nanopore sequencing and traditional short-read systems is essential.

1. Read Length

Traditional platforms generate short DNA fragments requiring computational reassembly.

CycloneSEQ reads long continuous DNA strands, enabling more accurate genome assembly.

2. Structural Variant Detection

Short-read sequencing may struggle with:

• Large insertions





• Repeat expansions





• Complex rearrangements

Long-read sequencing excels in resolving these genomic features.

3. Infrastructure and Accessibility

Traditional systems often require:

• Large-scale laboratory infrastructure





• High capital investment





• Significant operational overhead

CycloneSEQ offers greater flexibility and accessibility for emerging genomics laboratories.

4. Turnaround Time

Outsourcing sequencing abroad can delay research timelines.

With local genome sequencing now available in Nigeria at MyAfroDNA, turnaround time is significantly reduced.

5. Data Sovereignty

Local sequencing strengthens data ownership and supports African-led genomics research initiatives.

Why This Matters for Biotechnology in Nigeria and Africa

Africa contains the highest human genetic diversity globally, yet remains underrepresented in genomic databases.

The deployment of West Africa’s first CycloneSEQ nanopore sequencer strengthens:

• Precision medicine research





• Agricultural biotechnology





• Crop genome assembly





• Pathogen genomics





• Biodiversity and conservation research





• Academic and institutional genomics programs

By expanding DNA sequencing services in Nigeria, MyAfroDNA contributes to positioning Africa as an active contributor, not just a participant, in global genomics.

Frequently Asked Questions

What is nanopore sequencing?
Nanopore sequencing reads DNA directly as it passes through a protein pore, detecting electrical current changes to determine sequence information.

Is CycloneSEQ suitable for whole-genome sequencing?
Yes. It supports long-read whole-genome assembly and structural variant analysis.

Who can partner with MyAfroDNA?
Universities, biotech startups, hospitals, agricultural institutes, NGOs, pharmaceutical researchers, and international collaborators.

Is this technology only for human genomics?
No. It supports plant, microbial, animal, environmental, and metagenomic sequencing applications.

How can organizations access this service?
Institutions can contact MyAfroDNA to discuss project scope, sample type, volume requirements, and turnaround expectations.

Partner with MyAfroDNA

Partner with West Africa’s first nanopore sequencing facility.

MyAfroDNA now offers advanced genome sequencing services in Nigeria, serving researchers and institutions across West Africa, Africa, and globally.

If your organization requires:

• Long-read genome sequencing





• Structural variant analysis





• Agricultural genomics





• Pathogen surveillance





• Biodiversity sequencing





• Precision medicine research support

Our team is ready to collaborate.

Contact MyAfroDNA today to discuss your sequencing project and explore how CycloneSEQ technology can support your research objectives.

Cancer research is entering a transformative era. Precision oncology, the approach of tailoring cancer treatments based on a patient’s unique genetic profile, is already revolutionizing care in many parts of the world. However, recent evidence underscores a critical gap: precision oncology in Africa cannot succeed without African‑centric genomic data, infrastructure, and research partnerships. (Nature Africa, 2026)

Many of the genomic datasets driving current precision oncology tools are largely derived from populations outside Africa. While these datasets have enabled breakthroughs in diagnostics, therapy selection, and prognostic assessments, they do not capture the full spectrum of genetic diversity found in African populations. This matters because cancer development, mutation patterns, and drug responses are influenced by ancestry-specific genomic variations. Without representative African data, treatments risk being less effective or missing critical mutation patterns prevalent in African patients.

Why African Genomes Are Essential for Precision Oncology

The Nature Africa feature emphasizes that African populations possess high genetic diversity, one of the richest in the world. This diversity affects not only susceptibility to certain cancer types but also the effectiveness of targeted therapies. For example, mutations in genes such as TP53, BRCA1/2, or EGFR may appear with different frequencies or impact drug responses differently in African patients compared to non-African populations. Precision oncology that ignores this variation risks exacerbating health disparities, rather than reducing them.

The Role of Biobanking and Genomic Research

To build effective precision oncology for Africa, robust biobanks and genomic infrastructure are vital. Biobanks store ethically collected biological samples — including blood, tissue, saliva, and DNA — under controlled conditions for research. They allow researchers to:

• Identify population-specific genetic variants





• Map tumor evolution in African patients





• Develop diagnostic assays tailored to local mutation patterns





• Support clinical trials that reflect real-world African populations

Ethical stewardship and consent are central to biobanking. Samples must be traceable, stored securely, and used transparently for approved research. African biobanks like MyAfroDNA aim to provide this foundation while supporting collaborations with hospitals, universities, and research institutions.

Investing in African Genomic Capacity

Precision oncology requires more than samples; it needs trained personnel, advanced sequencing technologies, molecular tumor boards, and data analysis capacity. African researchers and clinicians must be empowered to interpret genomic information in context, linking mutations to effective therapies. Collaborative networks allow the sharing of resources, expertise, and knowledge to accelerate the translation of genomic insights into patient care.

Partner With MyAfroDNA for Precision Oncology for Africans by Africans

At MyAfroDNA, we are committed to advancing African-centric precision oncology through:

• Ethical biospecimen collection and storage





• Access to diverse African genomic samples for research





• Partnerships with researchers, hospitals, and institutions





• Training programs in genomic analysis and precision medicine

We invite researchers, universities, hospitals, and pharmaceutical companies to collaborate with us. By working together, we can ensure that precision oncology in Africa is informed by representative genomic data, supports tailored therapies, and contributes to equitable healthcare outcomes.

African genomic research is not just a scientific opportunity; it is a responsibility. Every sample, study, and collaboration strengthens the foundation for cancer care that is designed by Africans, for Africans.

Partner with MyAfroDNA today to advance precision oncology and genomic research in Africa.

Source: Nature Africa — Precision oncology specifically for Africa (nature.com)

Malaria remains one of Africa’s most persistent public health challenges, and early detection of disease vectors is critical to reducing transmission. A recent development in Madagascar highlights how artificial intelligence (AI) and citizen science are reshaping how malaria threats are identified and monitored across the continent.

According to a report by SciDev.Net, researchers used AI-powered image recognition tools alongside community participation to detect a potentially invasive malaria mosquito species, Anopheles stephensi, in Madagascar. This species is particularly concerning because it thrives in urban environments, breeding in water containers such as buckets, tyres, and tanks, settings where malaria transmission has traditionally been lower.

The detection was triggered when a citizen submitted a mosquito larva image via the NASA GLOBE Observer app. AI models trained on thousands of verified mosquito images classified the specimens with high confidence, demonstrating how digital tools can complement traditional entomological surveillance, especially in resource-limited settings.

For Africa, this approach has major implications. Conventional mosquito surveillance relies heavily on field trapping, microscopy, and laboratory confirmation, methods that are often expensive, slow, and unevenly distributed. AI-supported systems allow for rapid, scalable, and community-driven monitoring, improving early warning capacity and public health response.

At MyAfroDNA, we view this as part of a broader shift toward integrated genomic, digital, and environmental surveillance. Combining AI, biospecimen analysis, and genomic research can strengthen malaria control strategies, support vector mapping, and improve our understanding of how mosquito populations evolve and spread.

MyAfroDNA is actively seeking collaboration with researchers, public health institutions, universities, and malaria-focused organisations to support:

• Vector genomics and biospecimen research





• AI-assisted disease surveillance





• Data-driven malaria prevention strategies

Together, we can build African-led, evidence-based solutions for malaria research and control.

Reach out to collaborate with MyAfroDNA.

Source: SciDev.Net – AI and citizens detect invasive mosquito in Madagascar
https://www.scidev.net/sub-saharan-africa/news/ai-and-citizens-detect-invasive-mosquito-in-madagascar/